SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-167279
Filing Date
2021-05-20
Accepted
2021-05-20 08:30:32
Documents
14
Period of Report
2021-05-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d158157d8k.htm   iXBRL 8-K 33076
2 EX-10.1 d158157dex101.htm EX-10.1 133711
3 EX-99.1 d158157dex991.htm EX-99.1 9387
  Complete submission text file 0001193125-21-167279.txt   340387

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20210520.xsd EX-101.SCH 3084
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20210520_lab.xml EX-101.LAB 17373
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20210520_pre.xml EX-101.PRE 10962
7 EXTRACTED XBRL INSTANCE DOCUMENT d158157d8k_htm.xml XML 3246
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 21942434
SIC: 2834 Pharmaceutical Preparations